We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
-1.03%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$438M
AUM Growth
-$21.2M
Cap. Flow
+$25.3M
Cap. Flow %
5.78%
Top 10 Hldgs %
58.99%
Holding
62
New
9
Increased
15
Reduced
17
Closed
11
Avg Time Held
5.7 quarters
Top 10 Avg Time Held
5.5 quarters
Top 20 Avg Time Held
5.4 quarters

Top Buys

Rank Stock Value
1
IMNM icon
Immunome
IMNM
+$17.2M
2
CYTK icon
Cytokinetics
CYTK
+$12M
3
CRGX icon
CARGO Therapeutics
CRGX
+$10.6M
4
JBIO icon
Jade Biosciences
JBIO
+$8.34M
5
ARVN icon
Arvinas
ARVN
+$7.17M

Top Sells

Rank Stock Value
1
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$9.83M
2
OCUL icon
Ocular Therapeutix
OCUL
+$8.31M
3
CMPX icon
Compass Therapeutics
CMPX
+$6.28M
4
CPRX icon
Catalyst Pharmaceutical
CPRX
+$5.67M
5
NYXH icon
Nyxoah
NYXH
+$4.32M

Sector Composition

Rank Sector Weight
1 Healthcare 98.24%
2 Miscellaneous 1.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
HROW icon
1
Harrow
HROW
$1.09B
$83.4M 19.04%
3,990,000
+69,400
+2% +$1.04M
2018 Q3
23 quarters
TGTX icon
2
TG Therapeutics
TGTX
$8.46B
$40.6M 9.27%
2,280,000
– –
2023 Q3
3 quarters
OCUL icon
3
Ocular Therapeutix
OCUL
$1.66B
$36.3M 8.29%
5,307,500
-1,345,638
-20% -$8.31M
2019 Q1
21 quarters
RYTM icon
4
Rhythm Pharmaceuticals
RYTM
$6.18B
$21.1M 4.83%
515,000
– –
2022 Q2
8 quarters
KROS icon
5
Keros Therapeutics
KROS
$230M
$16.8M 3.84%
367,500
– –
2021 Q1
13 quarters
ARVN icon
6
Arvinas
ARVN
$487M
$14.8M 3.38%
555,000
+225,000
+68% +$7.17M
2023 Q4
2 quarters
IMNM icon
7
Immunome
IMNM
$2.26B
$13.3M 3.05%
+1,102,500
New +$17.2M
2024 Q2
0 quarters
CYTK icon
8
Cytokinetics
CYTK
$8.73B
$10.8M 2.46%
+198,500
New +$12M
2024 Q2
0 quarters
CDXS icon
9
Codexis
CDXS
$154M
$10.7M 2.45%
3,455,000
+335,000
+11% +$1.08M
2014 Q1
41 quarters
EWTX icon
10
Edgewise Therapeutics
EWTX
$4.18B
$10.4M 2.39%
580,000
-85,000
-13% -$1.48M
2022 Q1
9 quarters
CPRX icon
11
DELISTED
Catalyst Pharmaceutical
CPRX
$9.91M 2.27%
640,000
-364,355
-36% -$5.67M
2023 Q3
3 quarters
CRGX icon
12
DELISTED
CARGO Therapeutics
CRGX
$9.12M 2.08%
+555,700
New +$10.6M
2024 Q2
0 quarters
JSPR icon
13
Jasper Therapeutics
JSPR
$18.5M
$8.9M 2.03%
392,000
-43,573
-10% -$1.05M
2023 Q4
2 quarters
NRIX icon
14
Nurix Therapeutics
NRIX
$2.3B
$8.74M 2%
418,928
+151,718
+57% +$2.36M
2024 Q1
1 quarter
TRVI icon
15
Trevi Therapeutics
TRVI
$1.84B
$7.88M 1.8%
2,645,000
– –
2022 Q4
6 quarters
ETON icon
16
Eton Pharmaceutcials
ETON
$1.58B
$7.88M 1.8%
2,395,000
-50,781
-2% -$178K
2018 Q4
22 quarters
APLT icon
17
DELISTED
Applied Therapeutics
APLT
$7.85M 1.79%
1,680,000
-90,000
-5% -$426K
2023 Q3
3 quarters
FDMT icon
18
4D Molecular Therapeutics
FDMT
$718M
$7.26M 1.66%
345,750
+1,627
+0.5% +$40.8K
2021 Q4
10 quarters
IOVA icon
19
Iovance Biotherapeutics
IOVA
$6.6B
$7.19M 1.64%
897,000
– –
2023 Q1
5 quarters
SLRN icon
20
DELISTED
ACELYRIN
SLRN
$6.97M 1.59%
1,580,000
– –
2023 Q2
4 quarters
URGN icon
21
UroGen Pharma
URGN
$1.87B
$6.91M 1.58%
412,000
+142,000
+53% +$2.02M
2022 Q2
8 quarters
PCVX icon
22
Vaxcyte
PCVX
$11B
$6.42M 1.47%
85,000
– –
2020 Q3
15 quarters
BDSX icon
23
Biodesix
BDSX
$271M
$6.15M 1.41%
201,000
+174,267
+652% +$4.98M
2023 Q3
3 quarters
NAMS icon
24
NewAmsterdam Pharma
NAMS
$2.54B
$6.05M 1.38%
315,000
-388
-0.1% -$7.78K
2023 Q4
2 quarters
XOMA icon
25
DELISTED
Xoma
XOMA
$5.92M 1.35%
250,000
– –
2017 Q1
29 quarters
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q2 2024 Portfolio in Review

As of Q2 2024, Opaleye Management held 62 positions worth $438M, down 4.6% from $459M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Opaleye Management deployed $25.3M of net new capital in Q2 2024, opening 9 new positions and adding to 15 existing holdings. Its largest new stake was Immunome: 1,102,500 shares worth $13.3M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Ocular Therapeutix, an estimated $8.31M trimmed.

  • Opaleye Management's largest Q2 2024 buy was Immunome: 1,102,500 shares worth $13.3M.
  • Opaleye Management added most to Arvinas in Q2 2024, an estimated $7.17M increase.
  • Opaleye Management's biggest Q2 2024 reduction was Ocular Therapeutix, cutting an estimated $8.31M.
  • Opaleye Management fully exited Crinetics Pharmaceuticals in Q2 2024, selling an estimated $9.83M.
  • Opaleye Management's ten largest holdings make up 59% of its $438M portfolio in Q2 2024.
  • Opaleye Management opened 9 new positions and closed 11 in Q2 2024.
  • Opaleye Management's portfolio value fell 4.6% quarter-over-quarter to $438M.

Based on Opaleye Management's 13F filing for Q2 2024, filed 14 Aug 2024.